Lipids & metabolic liver disease
Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
Authors' conclusion
Abnormalities in the metabolism of intestinally derived ApoB-48-containing lipoproteins in individuals with type 2 diabetes on statins may help to explain the residual risk of CVD and may be suitable targets for interventions.
Study context
- Population
- Overweight/obese individuals with T2D on metformin and statin therapy, and matched controls on statins
- Participants
- 11 vs 11
- Comparison
- T2D on statins vs matched controls on statins
- T2Dn = 11
- Controlsn = 11reference
- Primary endpoint
- Kinetics of ApoB-48 (chylomicrons, VLDL), ApoB-100 (VLDL, IDL, LDL) and VLDL TG in response to a standard fat-rich meal
Methodological detailsmechanistic kinetic study, case-control comparison, frequency-matched for age, BMI and sex, stable isotope tracers, standard fat-rich meal
- Mechanistic kinetic study
- Case-control comparison
- Frequency-matched for age, BMI and sex
- Stable isotope tracers
- Standard fat-rich meal
Primary result
As reported in the abstract
ApoB-48 kinetics
Postprandial ApoB-48 share of total VLDL: T2D vs controls
44% vs 25%
Further findings
Fasting lipid profile
- Did not differ significantly between groups
ApoB-100 and triglyceride (TG) kinetics
- No between-group differences in VLDL ApoB-100 and TG kinetics, or LDL ApoB-100 production, pool size and clearance
- Intermediate-density lipoprotein (IDL) ApoB-100 pool higher in T2D due to increased conversion from VLDL2
Original publication
Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy. Diabetologia. Published 29 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →